AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31805675 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbs and Spices (H&S) added to low-salt legume-based dishes (0.4% w/w)
Number of subjects: 94
Study 31805675 — intervention group
Group type: COMPARATOR
Intervention: Low-salt legume-based dishes (0.4% w/w) without H&S (LS)
Number of subjects: 94
Study 31805675 — intervention group
Group type: COMPARATOR
Intervention: Standard salt legume-based dishes (0.8% w/w) (S)
Number of subjects: 94
Study 31805675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt legume-based dishes with H&S (LSHS)
Number of subjects: 94
Study 27570169 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella tendon autograft (BPTB)
Number of subjects: 27
Study 27570169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring autograft (HS)
Number of subjects: 27
Study 27570169 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibialis anterior allograft (TA)
Number of subjects: 27
Study 27570169 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 26382279 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a
Number of subjects: 76
Study 26382279 — intervention group
Group type: COMPARATOR
Intervention: interferon alpha-2a
Number of subjects: 76
Study 24510496 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g twice daily of creatine monohydrate
Number of subjects: 64
Study 24510496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22237819 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT) treatment (n = 8)
Number of subjects: 16
Study 22237819 — intervention group
Group type: COMPARATOR
Intervention: placebo-control (n = 8)
Number of subjects: 16
Study 20064185 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL PDT (methyl aminolevulinate) applied as cream 160 mg/g for 3 hours, followed by illumination with broad-spectrum red light (75 J/cm², 570-670 nm), repeated 7 days later.
Number of subjects: 131
Study 20064185 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied for 3 hours, followed by illumination with broad-spectrum red light (75 J/cm², 570-670 nm), repeated 7 days later.
Number of subjects: 131
Study 20064185 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL PDT (methyl aminolevulinate)
Number of subjects: 131
Study 17457126 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg/kg scopolamine
Number of subjects: 100
Study 17457126 — intervention group
Group type: COMPARATOR
Intervention: 10 microg/kg atropine
Number of subjects: 100
Study 15050067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hertel exophthalmometry
Number of subjects: 32
Study 15050067 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical 3D imaging
Number of subjects: 32
Study 15050067 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography
Number of subjects: 32
Study 12182270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Processing Therapy (CPT)
Number of subjects: 171
Study 12182270 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 171
Study 12182270 — intervention group
Group type: COMPARATOR
Intervention: Minimal Attention (MA)
Number of subjects: 171
Study 9696367 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) consolidation and reintensification
Number of subjects: 3500
Study 9696367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of multidrug induction, HD-MTX consolidation, and reintensification
Number of subjects: 3500
Study 9696367 — intervention group
Group type: COMPARATOR
Intervention: Conventional doses of methotrexate
Number of subjects: 3500
Study 9696367 — intervention group
Group type: EXPERIMENTAL
Intervention: Short intensive chemotherapy pulses including HD-MTX
Number of subjects: 3500
Study 9696367 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-consolidation cranial radiotherapy (CRT)
Number of subjects: 3500
Study 7848669 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained residents delivering stage-based smoking cessation advice
Number of subjects: 252
Study 7848669 — intervention group
Group type: COMPARATOR
Intervention: Untrained residents (usual care)
Number of subjects: 252
Study 2503640 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid polymer diet (Fresubin)
Number of subjects: 10
Study 2503640 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraduodenal application of liquid hydrolysed diet (Survimed OPD)
Number of subjects: 10
Study 2503640 — intervention group
Group type: COMPARATOR
Intervention: Standardized normal meal
Number of subjects: 10
Study 403921 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 33
Study 403921 — intervention group
Group type: COMPARATOR
Intervention: Gold
Number of subjects: 33
Study 403921 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 33
Study 31159655 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric jump training with 30s inter-set recovery
Number of subjects: 0
Study 31159655 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric jump training with 120s inter-set recovery
Number of subjects: 0
Study 31159655 — intervention group
Group type: COMPARATOR
Intervention: Control period (no plyometric training)
Number of subjects: 0
Study 28637287 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-EP2006
Number of subjects: 624
Study 28637287 — intervention group
Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 624
Study 25851616 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 391
Study 25851616 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotics
Number of subjects: 391
Study 23265705 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) and lapatinib followed by lapatinib
Number of subjects: 67
Study 23265705 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CRT) and placebo followed by placebo
Number of subjects: 67
Study 20950940 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 176
Study 20950940 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed subjects
Number of subjects: 176
Study 20950940 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated patients
Number of subjects: 176
Study 20950940 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated patients
Number of subjects: 176
Study 19433150 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching Our Acting‐Out Children: Heightening Essential Skills (COACHES) program
Number of subjects: 0
Study 19433150 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Parent Training (BPT) program
Number of subjects: 0
Study 17084249 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 10, 30, 60, or 90 mg/day
Number of subjects: 162
Study 17084249 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 90 mg/day
Number of subjects: 162
Study 17084249 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 60 mg/day
Number of subjects: 162
Study 17084249 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 162
Study 17084249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 15588745 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Diaries
Number of subjects: 177
Study 15588745 — intervention group
Group type: COMPARATOR
Intervention: T-Diaries
Number of subjects: 177
Study 15588745 — intervention group
Group type: COMPARATOR
Intervention: P-Diaries
Number of subjects: 177
Study 15588745 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 177
Study 11748389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 49
Study 11748389 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (control)
Number of subjects: 49
Study 9280206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt restriction with a low-salt diet (20 mmol sodium chloride per day) and a supplement of 20 tablets of slow sodium (10 mmol NaCl per tablet) for 7 days
Number of subjects: 90
Study 8301803 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN during chemotherapy
Number of subjects: 43
Study 8301803 — intervention group
Group type: COMPARATOR
Intervention: CT only
Number of subjects: 43
Study 8301803 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN
Number of subjects: 43
Study 8301803 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 43
Study 3546185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 52
Study 3546185 — intervention group
Group type: COMPARATOR
Intervention: Hypaque M60
Number of subjects: 52
Study 30956054 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin intervention group
Number of subjects: 69
Study 28062538 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline estimated pulmonary artery diastolic pressure (ePAD)
Number of subjects: 790
Study 28062538 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ePAD from baseline to 6 months
Number of subjects: 790
Study 28062538 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ePAD from baseline to 14 days before death or exit from study
Number of subjects: 790
Study 28062538 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the pressure versus time curve in the final 180 days before death or exit from study
Number of subjects: 790
Study 25436635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets × 8 repetitions × 3‐minute recovery at 70% 1RM
Number of subjects: 0
Study 25436635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets × 14 repetitions × 3‐minute recovery at 40% 1RM
Number of subjects: 0
Study 25436635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets × MNR (maximum number of repetitions) × 1‐minute recovery at 70% 1RM
Number of subjects: 0
Study 25436635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets × MNR × 3‐minute recovery at 70% 1RM
Number of subjects: 0
Study 25436635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets × MNR × 1‐minute recovery at 40% 1RM
Number of subjects: 0
Study 25436635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets × MNR × 3‐minute recovery at 40% 1RM
Number of subjects: 0
Study 25436635 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute postexercise
Number of subjects: 0
Study 25436635 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute postexercise
Number of subjects: 0
Study 23489113 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of terlipressin (4 mg/24 h)
Number of subjects: 20
Study 23489113 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of terlipressin (2 mg) followed by intermittent injections (1 mg/6 h)
Number of subjects: 20
Study 21520588 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil anesthesia (R)
Number of subjects: 51
Study 21520588 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (E)
Number of subjects: 51
Study 18623165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric onset IBD patients
Number of subjects: 368
Study 18623165 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 368
Study 16415702 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 64
Study 16415702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15046380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg)
Number of subjects: 127
Study 15046380 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5 mg)
Number of subjects: 127
Study 15046380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg)
Number of subjects: 127
Study 15046380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 15046380 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs (nimesulide, meloxicam, rofecoxib)
Number of subjects: 127
Study 11467457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-coil lead system
Number of subjects: 83
Study 11467457 — intervention group
Group type: COMPARATOR
Intervention: Single-coil lead system
Number of subjects: 83
Study 9836480 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Number of subjects: 4
Study 9836480 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (single-agent, higher dose)
Number of subjects: 4
Study 8157946 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (average dose 72 mg/day for 24 weeks)
Number of subjects: 26
Study 8157946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2844031 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV vaccine
Number of subjects: 42
Study 2844031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28893496 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist hot pack (MHP) for 15 minutes during therapy
Number of subjects: 60
Study 28893496 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic whirlpool bath (WB) for 15 minutes during therapy
Number of subjects: 60
Study 27522105 — intervention group
Group type: EXPERIMENTAL
Intervention: Trima Accel cell separator
Number of subjects: 110
Study 25106447 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-careldopa treatment in addition to routine NHS occupational and physical therapy
Number of subjects: 0
Study 25106447 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in addition to routine NHS occupational and physical therapy
Number of subjects: 0
Study 23432657 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 37
Study 23432657 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with connective tissue graft (CAF+CTG)
Number of subjects: 37
Study 23432657 — intervention group
Group type: COMPARATOR
Intervention: Control group (CAF)
Number of subjects: 37
Study 19926182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal septal cartilage graft
Number of subjects: 22
Study 19926182 — intervention group
Group type: COMPARATOR
Intervention: Conchal cartilage graft
Number of subjects: 22
Study 17595175 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate incentives ($5 weekly)
Number of subjects: 0
Study 17595175 — intervention group
Group type: COMPARATOR
Intervention: Delayed incentives ($5 at program end)
Number of subjects: 0
Study 17595175 — intervention group
Group type: EXPERIMENTAL
Intervention: Media recruitment method
Number of subjects: 0
Study 17595175 — intervention group
Group type: COMPARATOR
Intervention: Non-media recruitment method
Number of subjects: 0
Study 17595175 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study 17243432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.1%
Number of subjects: 45
Study 17243432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11850090 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine placebo
Number of subjects: 159
Study 11850090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 11850090 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind condition
Number of subjects: 159
Study 9602959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 50 mg
Number of subjects: 304
Study 9602959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 100 mg
Number of subjects: 304
Study 9602959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 304
Study 9602959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 304
Study 9602959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 9602959 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication (Acetaminophen 500 mg)
Number of subjects: 304
Study 8027413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (225 to 450 mg/day)
Number of subjects: 124
Study 8027413 — intervention group
Group type: COMPARATOR
Intervention: Trazodone (150 to 400 mg/day)
Number of subjects: 124
Study 8027413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 124
Study 8027413 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 124
Study 2660893 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 544
Study 2660893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 4851085 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP treatment plus bleomycin
Number of subjects: 0
Study 4851085 — intervention group
Group type: COMPARATOR
Intervention: MOPP treatment
Number of subjects: 0
Study 4851085 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP treatment (maintained group for 24 months)
Number of subjects: 0
Study 30676666 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20-30 training concept (n=12)
Number of subjects: 22
Study 30676666 — intervention group
Group type: COMPARATOR
Intervention: sprint interval training (SIT, n=10; work/rest ratio: 6-s/54-s)
Number of subjects: 22
Study 30676666 — intervention group
Group type: COMPARATOR
Intervention: sprint interval training (SIT)
Number of subjects: 22
Study 28177725 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidic acid (PA) supplementation (750 mg)
Number of subjects: 15
Study 28177725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study 23999311 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (2×10‐15 repetitions at 80% of one repetition maximum (1RM))
Number of subjects: 56
Study 23999311 — intervention group
Group type: COMPARATOR
Intervention: LOW (1×80‐100 repetitions at 20% of 1RM)
Number of subjects: 56
Study 23999311 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW+ (1×60 repetitions at 20% of 1RM, followed by 1×10‐20 repetitions at 40% of 1RM)
Number of subjects: 56
Study 23999311 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH
Number of subjects: 56
Study 21419542 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 26
Study 21419542 — intervention group
Group type: COMPARATOR
Intervention: Rotatory osteotomy
Number of subjects: 26
Study 21419542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 26
Study 21419542 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery and Rotatory osteotomy
Number of subjects: 26
Study 19640521 — intervention group
Group type: EXPERIMENTAL
Intervention: Alimaxx-E stent placement
Number of subjects: 45
Study 19640521 — intervention group
Group type: COMPARATOR
Intervention: Alimaxx-E stent placement over endoscope
Number of subjects: 45
Study 18341817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher stents
Number of subjects: 8190
Study 18341817 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS stents
Number of subjects: 8190
Study 18341817 — intervention group
Group type: EXPERIMENTAL
Intervention: Firebird stents
Number of subjects: 8190
Study 15531538 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-stimulated COH cycles
Number of subjects: 0
Study 15531538 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 0
Study 15531538 — intervention group
Group type: COMPARATOR
Intervention: Natural cycles
Number of subjects: 0
Study 11376826 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration <0.09 s
Number of subjects: 1100
Study 11376826 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration between 0.09 and 0.11 s
Number of subjects: 1100
Study 11376826 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration >0.11 s
Number of subjects: 1100
Study 9535996 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM 20 mg/70 kg i.v.
Number of subjects: 6
Study 9535996 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM 40 mg/70 kg i.v.
Number of subjects: 6
Study 9535996 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM 20 mg/70 kg p.o.
Number of subjects: 6
Study 9535996 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM 40 mg/70 kg p.o.
Number of subjects: 6
Study 9535996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8070500 — intervention group
Group type: EXPERIMENTAL
Intervention: U-62066E
Number of subjects: 10
Study 8070500 — intervention group
Group type: EXPERIMENTAL
Intervention: U-62066E with high dose naloxone
Number of subjects: 10
Study 8070500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8070500 — intervention group
Group type: EXPERIMENTAL
Intervention: U-62066E with low dose naloxone
Number of subjects: 10
Study 2653893 — intervention group
Group type: EXPERIMENTAL
Intervention: gemeprost 1 mg vaginal pessaries at 3 hours intervals up to a maximum of 5 mg
Number of subjects: 152
Study 2653893 — intervention group
Group type: COMPARATOR
Intervention: PGF2 alpha 40 mg intra-amniotic dose
Number of subjects: 152
Study 2653893 — intervention group
Group type: EXPERIMENTAL
Intervention: gemeprost
Number of subjects: 152
Study 2653893 — intervention group
Group type: COMPARATOR
Intervention: PGF2 alpha
Number of subjects: 152
Study 1091343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (sustained-release capsule and regular tablet)
Number of subjects: 622
Study 1091343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study 30566602 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine
Number of subjects: 0
Study 30566602 — intervention group
Group type: COMPARATOR
Intervention: Unadjuvanted H5N1 vaccine
Number of subjects: 0
Study 29911772 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% minoxidil solution
Number of subjects: 20
Study 29911772 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% minoxidil milky lotion
Number of subjects: 20
Study 24588955 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-layer silicone bordered dressings (Mepilex Border Sacrum(®) and 3 layer Mepilex Heel(®) dressings by Mölnlycke Health Care)
Number of subjects: 0
Study 23291775 — intervention group
Group type: EXPERIMENTAL
Intervention: Essence of chicken
Number of subjects: 12
Study 23291775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20852438 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine bid (twice daily)
Number of subjects: 75